Sun Pharma unveils Ezallor Sprinkle capsules for treating lipid disorder in US

Ezallor Sprinkle (rosuvastatin) capsules are indicated for three types of lipid disorders in conjunction with diet in adults, Sun Pharma said in a regulatory filing.

New Delhi: Sun Pharma Monday announced the launch of Ezallor Sprinkle capsules, used for the treatment of elevated lipid disorders in people who have difficulty swallowing, in the US market.

Ezallor Sprinkle (rosuvastatin) capsules are indicated for three types of lipid disorders in conjunction with diet in adults, Sun Pharma said in a regulatory filing.

The company said this problem is estimated to affect approximately 30-35 per cent of long-term care residents.

Also Read: Sun Pharma former RnD head murders family of three, then commits suicide

"With the introduction of Ezallor Sprinkle, Sun Pharma continues our commitment of providing a portfolio of alternative formulation products to address the needs of people who have difficulty swallowing, which is especially prevalent among residents in long-term care facilities," Sun Pharma North America CEO Abhay Gandhi said.

"These patients often encounter more medication errors and challenges with medication administration as compared to long-term care residents who do not have difficulty swallowing," he added.

Also Read: Sun Pharma Research Arm- SPARC gets USFDA orphan drug designation for novel kinase inhibitor